Exicure Stock (NASDAQ:XCUR)
Previous Close
$3.94
52W Range
$1.44 - $6.00
50D Avg
$2.81
200D Avg
$2.55
Market Cap
$12.64M
Avg Vol (3M)
$1.09M
Beta
1.28
Div Yield
-
XCUR Company Profile
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
XCUR Performance
Peer Comparison
| Ticker | Company |
|---|---|
| SCPH | scPharmaceuticals Inc. |
| MCRB | Seres Therapeutics, Inc. |
| LIFE | aTyr Pharma, Inc. |
| CYCC | Cyclacel Pharmaceuticals, Inc. |
| CBIO | Gyre Therapeutics, Inc. |
| DMAC | DiaMedica Therapeutics Inc. |
| MRKR | Marker Therapeutics, Inc. |
| ONCY | Oncolytics Biotech Inc. |
| MIST | Milestone Pharmaceuticals Inc. |
| ENOB | Renovaro Biosciences Inc. |
| LUMO | Lumos Pharma, Inc. |